11 completed, 9 terminated, 3 unknown, 1 withdrawn. 17 Phase 2, 12 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Terminated 8, Completed 5, Unknown 3, Withdrawn 1 |
| Phase 1 | 12 | Completed 8, Unknown 2, Terminated 1, Withdrawn 1 |
Follow Interleukin-7: new trials by email Literature Review of Interleukin-7 trials Research Report on Interleukin-7
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) Interleukin-7, PLACEBO - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 4 | 2021-03-01 | 2024-04-12 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) CYT107, Placebo - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 10 | 2020-12-20 | 2024-04-11 |
| Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease Recombinant human interleukin-7 - Mycobacterium Infections, Nontuberculous | Phase 2 | Terminated | Revimmune | 8 | 2020-11-30 | 2024-04-11 |
| 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II Recombinant Interleukin-7 - Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 1 | 2020-09-29 | 2024-10-17 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) CYT107, Placebo - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 26 | 2020-09-15 | 2022-04-08 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort Interleukin-7, Placebo - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 34 | 2020-06-08 | 2022-04-08 |
| InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort Interleukin-7, Placebos - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 35 | 2020-05-14 | 2022-04-07 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma. Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells - B Cell Lymphoma | Phase 2 | Unknown | Wenbin Qian | 80 | 2019-03-28 | 2019-04-26 |
| Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation CYT107 - Umbilical Cord Blood Transplant | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2018-11-01 | 2019-01-10 | |
| Immune Reconstitution of Immunosuppressed Sepsis Patients Interleukin-7, Placebo - Severe Sepsis With Septic Shock | Phase 2 | Terminated | University Hospital, Limoges | 16 | 2016-01-14 | 2017-11-29 |
| A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients Interleukin-7, Placebo - Severe Sepsis With Septic Shock | Phase 2 | Completed | Revimmune | 27 | 2016-01-01 | 2020-07-09 |
| Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients placebo, interleukin 7 - Metastatic Breast Cancer | Phase 2 | Completed | Centre Leon Berard | 24 | 2011-06-01 | 2015-02-09 |
| Study on Interleukin-7 (CYT107) in HIV Patients Interleukin-7 - HIV | Phase 2 | Terminated | Cytheris SA | 23 | 2010-01-01 | 2013-08-01 |
| Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in Asiatic HCV Patients Resistant to Bitherapy Interleukin-7 - Hepatitis C | Phase 1 / Phase 2 | Unknown | Cytheris SA | 15 | 2009-01-01 | 2012-10-18 |
| Dose Escalation Study of Interleukin-7 (IL-7) and Bitherapy in HCV Genotype 1 or 4 Patients Resistant to Bitherapy Alone Interleukin-7 - Hepatitis C | Phase 1 / Phase 2 | Unknown | Cytheris SA | 18 | 2008-07-01 | 2012-10-18 |
| Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107) - AML, CML | Phase 1 | Completed | Cytheris, Inc. | 12 | 2008-03-01 | 2012-07-26 |
| Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1) Interleukin-7 - Hepatitis C | Phase 1 / Phase 2 | Completed | Cytheris SA | 10 | 2007-05-01 | 2012-10-18 |
| Safety Study of IL-7 in HIV-infected Patients (Inspire) CYT 107 - HIV Infections, Lymphopenia | Phase 1 | Completed | Cytheris SA | 30 | 2007-05-01 | 2012-10-18 |
| Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer recombinant interleukin-7, gene expression analysis, polymerase chain reaction - Kidney Cancer, Melanoma (Skin) | Phase 1 | Terminated | Cytheris SA | 9 | 2007-05-01 | 2012-10-18 |
Showing 20 of 24. Sign in to see all of them.
Lymphopenia (8) · COVID-19 (5) · Virus Diseases (4) · HIV Infections (3) · Hepatitis C (3) · Hepatitis, Chronic (3) · Liver Diseases (3) · Melanoma (2) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Carcinoma, Transitional Cell (1) · Graft vs Host Disease (1) · Infections (1) · Kidney Neoplasms (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)
Revimmune (7) · Cytheris SA (6) · M.D. Anderson Cancer Center (2) · National Cancer Institute (NCI) (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Centre Leon Berard (1) · Cytheris, Inc. (1) · National Institutes of Health Clinical Center (CC) (1) · University Hospital, Limoges (1) · Wenbin Qian (1)
United States (14) · France (6) · Italy (3) · Canada (2) · Switzerland (2) · Brazil (1) · China (1) · Taiwan (1) · United Kingdom (1)
Marcel van den Brink, MD, PhD (2) · Steven A. Rosenberg, MD, PhD (2) · Tilman Gerlach (2) · Claude Sportes, MD (1) · David Marin, MD (1) · Evan Y Yu (1) · Gheath Al-Atrash (1) · Irini Sereti (1) · Irini Sereti, MD (1) · Isabelle Ray Coquart (1) · Manu Shankar-Hari, MD PhD (1)
PMID 29515037, PMID 39903535, PMID 32031570, PMID 32171076, PMID 16699374, PMID 19287090, PMID 19380868, PMID 23053510, PMID 10561360, PMID 10737767, PMID 12010786, PMID 12411295, PMID 12519925, PMID 12610500, PMID 12759326, PMID 12816983, PMID 14615453, PMID 15503313, PMID 15569976, PMID 15629410, PMID 15841203, PMID 15905493, PMID 16557261, PMID 17135638, PMID 17320482, PMID 18573906, PMID 18946659, PMID 19244125, PMID 19396174, PMID 19424209, PMID 19549917, PMID 19808962, PMID 19933849, PMID 20068111, PMID 21153402, PMID 21508983, PMID 22187279, PMID 22383042, PMID 22550117, PMID 22693226, PMID 23012326, PMID 23427891, PMID 23589672, PMID 24232462, PMID 26908786, PMID 40351870, PMID 8636781, PMID 9215626, PMID 9657738
R01CA061508 (2), P30CA015704 (1), U01CA154967 (1)